Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperkalemia represents a serious complication in maintenance hemodialysis (MHD) patients, significantly increasing risks of all-cause mortality, cardiovascular events, and hospitalization. Current management is complicated by comorbidities, medication-related potassium elevation, and complex dietary restrictions, creating an urgent need for innovative strategies. Digital cognitive behavioral therapy (dCBT) offers a promising approach through behavior modification but its efficacy for hyperkalemia management remains unestablished.
This single-center randomized controlled trial enrolled 73 MHD patients with recurrent hyperkalemia. Participants were allocated to receive either 8 weeks of smartphone-based dCBT plus standard care (n=37) or standard care alone (n=36), followed by 4 weeks of observation. The primary outcome was change in serum potassium from baseline to week 8. Secondary outcomes included serum phosphate, quality of life (KDQOL-36), self-efficacy (GSES), and medication adherence (MMAS-8), .assessed at baseline, week 4, week 8 (end of intervention), and week 12 (follow-up). Analysis employed repeated-measures ANOVA with appropriate post-hoc testing.
The dCBT group demonstrated significantly greater reduction in serum potassium compared to controls (group-by-time interaction P=0.002). Serum potassium decreased from 5.73±0.45 mmol/L to 5.02±0.47 mmol/L at week 8 in the dCBT group, remaining stable at follow-up (5.05±0.51 mmol/L), with significantly lower levels versus control (5.29±0.52 mmol/L) at week 8 (P=0.010). The dCBT group also showed substantial improvements in physical health-related quality of life, self-efficacy, and medication adherence. No significant between-group differences were observed in serum phosphate levels.
Digital cognitive behavioral therapy effectively reduces serum potassium levels and improves key patient-reported outcomes in MHD patients with hyperkalemia. The intervention demonstrates sustained effects and represents a comprehensive approach to hyperkalemia management that addresses both physiological and behavioral aspects of care. These findings support the integration of dCBT into standard renal care protocols for improved hyperkalemia management.
